Knight Therapeutics (TSE:GUD) has released an update.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Knight Therapeutics has reported record revenues for the second quarter of 2024, showcasing a significant increase in both revenue and adjusted EBITDA compared to the previous year. The company credits the growth to its key promoted products and commercial execution in Canada and Latin America, despite a net loss and outflow of cash from operations.
For further insights into TSE:GUD stock, check out TipRanks’ Stock Analysis page.
